A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Public ClinicalTrials.gov record NCT04294667. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
Study identification
- NCT ID
- NCT04294667
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 321 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 12, 2020 (Actual)
- Primary completion
- May 22, 2024 (Actual)
- Completion
- Jun 4, 2024 (Actual)
- Last update posted
- May 4, 2025
2020 – 2024
United States locations
- U.S. sites
- 60
- U.S. states
- 24
- U.S. cities
- 56
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sl0043 50140 | Birmingham | Alabama | 35205 | — |
| Sl0043 50052 | Phoenix | Arizona | 85032 | — |
| Sl0043 50328 | Tucson | Arizona | 85704 | — |
| Sl0043 50383 | Beverly Hills | California | 90211 | — |
| Sl0043 50257 | La Jolla | California | 92037 | — |
| Sl0043 50275 | La Palma | California | 90623-1730 | — |
| Sl0043 50378 | Loma Linda | California | 92354 | — |
| Sl0043 50258 | Los Angeles | California | 90022 | — |
| Sl0043 50340 | Orange | California | 92868 | — |
| Sl0043 50331 | Poway | California | 92064 | — |
| Sl0043 50377 | San Diego | California | 92108 | — |
| Sl0043 50316 | San Leandro | California | 94578 | — |
| Sl0043 50339 | Denver | Colorado | 80230 | — |
| Sl0043 50367 | New Haven | Connecticut | 06519 | — |
| Sl0043 50341 | Washington D.C. | District of Columbia | 20060 | — |
| Sl0043 50239 | Brandon | Florida | 33511 | — |
| Sl0043 50362 | Gainesville | Florida | 32610 | — |
| Sl0043 50122 | Miami | Florida | 33136 | — |
| Sl0043 50059 | Ormond Beach | Florida | 32174 | — |
| Sl0043 50324 | Plantation | Florida | 33324 | — |
| Sl0043 50329 | Tampa | Florida | 33606 | — |
| Sl0043 50283 | Tampa | Florida | 33613 | — |
| Sl0043 50368 | Atlanta | Georgia | 30303 | — |
| Sl0043 50382 | Atlanta | Georgia | 30309 | — |
| Sl0043 50240 | Idaho Falls | Idaho | 83404 | — |
| Sl0043 50310 | Chicago | Illinois | 60612 | — |
| Sl0043 50360 | Skokie | Illinois | 60076 | — |
| Sl0043 50474 | Hopkinsville | Kentucky | 42240-1746 | — |
| Sl0043 50285 | Lake Charles | Louisiana | 70605 | — |
| Sl0043 50288 | Cumberland | Maryland | 21502 | — |
| Sl0043 50015 | Hagerstown | Maryland | 21740 | — |
| Sl0043 50219 | Detroit | Michigan | 48201 | — |
| Sl0043 50333 | Grand Blanc | Michigan | 48439 | — |
| Sl0043 50273 | Las Vegas | Nevada | 89128 | — |
| Sl0043 50010 | Brooklyn | New York | 11201 | — |
| Sl0043 50366 | Canton | New York | 13617 | — |
| Sl0043 50266 | Great Neck | New York | 11021 | — |
| Sl0043 50264 | Manhasset | New York | 11030 | — |
| Sl0043 50077 | New York | New York | 10021 | — |
| Sl0043 50334 | New York | New York | 10032 | — |
| Sl0043 50241 | Syracuse | New York | 13210 | — |
| Sl0043 50238 | Charlotte | North Carolina | 28211 | — |
| Sl0043 50179 | Winston-Salem | North Carolina | 27157-1010 | — |
| Sl0043 50330 | Cincinnati | Ohio | 45242 | — |
| Sl0043 50262 | Oklahoma City | Oklahoma | 73104 | — |
| Sl0043 50020 | Duncansville | Pennsylvania | 16635 | — |
| Sl0043 50147 | Hershey | Pennsylvania | 17033 | — |
| Sl0043 50364 | Philadelphia | Pennsylvania | 19107 | — |
| Sl0043 50365 | Pittsburgh | Pennsylvania | 15232 | — |
| Sl0043 50001 | Jackson | Tennessee | 38305 | — |
| Sl0043 50263 | Amarillo | Texas | 79124 | — |
| Sl0043 50338 | Bellaire | Texas | 77401 | — |
| Sl0043 50418 | Colleyville | Texas | 76034 | — |
| Sl0043 50057 | Dallas | Texas | 75231 | — |
| Sl0043 50304 | Dallas | Texas | 75390 | — |
| Sl0043 50036 | Mesquite | Texas | 75150 | — |
| Sl0043 50267 | Seattle | Washington | 98195 | — |
| Sl0043 50061 | Spokane | Washington | 99204 | — |
| Sl0043 50050 | Beckley | West Virginia | 25801 | — |
| Sl0043 50321 | Morgantown | West Virginia | 26505 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 117 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04294667, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 4, 2025 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04294667 live on ClinicalTrials.gov.